Iopidine (Apraclonidine Hydrochloride)

Apraclonidine, the active ingredient in Iopidine, activates alpha‑2 adrenergic receptors in the ciliary body. This action decreases the production of aqueous humor and increases uveoscleral outflow, resulting in a net reduction of intraocular pressure.

The dosing regimen for Iopidine is determined by the prescribing eye‑care professional based on the patient’s condition and response. Typically, one or two drops are instilled in the affected eye(s) as directed by the clinician.

Safety data for apraclonidine in pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made by the treating physician.

To order Iopidine, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Iopidine belongs to the alpha‑2 adrenergic agonist class, which lowers eye pressure by reducing aqueous humor production. Compared with beta‑blocker drops, it has a different mechanism and may be used when beta‑blockers are contraindicated or as an adjunct to achieve additional pressure reduction.

Iopidine should be stored at room temperature, ideally below 25 °C. Keep the bottle in its original packaging, protect it from direct light and moisture, and ensure the cap is tightly closed when not in use.

Iopidine is applied as an ophthalmic solution. The patient instills the prescribed number of drops into the affected eye(s) using the provided dropper, typically after washing hands and avoiding contact between the tip and the eye or any surface.

Serious risks include severe allergic reactions such as angioedema, persistent ocular inflammation, and systemic hypotension that may cause dizziness or fainting. Any signs of these reactions require immediate medical attention and discontinuation of the drug.

Iopidine should not be used by individuals with known hypersensitivity to apraclonidine or any component of the formulation. Caution is also advised for patients with uncontrolled cardiovascular disease, severe ocular surface disease, or those already receiving multiple ocular hypotensive agents without specialist supervision.